Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-02-23
1998-09-15
Low, Christopher S. F.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 12, 435325, 4351723, 4353201, 424 9321, 536 243, 536 231, A01N 4304
Patent
active
058078363
ABSTRACT:
The present invention relates, in general, to a method of diagnosing tumorigenic mammalian cells or the propensity of a mammalian cell to become tumorigenetic. Additionally, the present invention relates to a cloned cDNA or genomic DNA for reducing the propensity of a cell to become tumorigenic or suppressing tumorigenic phenotype of a cell; a method of reducing the propensity of a cell to become tumorigenic or suppressing the tumorigenic phenotype of a cell; a method of treating a patient suffering from or predisposed to subsequent cancer development; and a method of diagnosing tumorigenic tissue of a human or tissue predisposed to become tumorigenic.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
Marsfall, Science, vol. 270, p: 1751, 1995.
Ledley, Ham. Gene Ther., 1995, 6: 1129-1144, 1995.
Mastragelo, Seminar in Oncology, vol. 23, 1: 4-21, 1996.
Coghlan, New Scientist, vol. 148, pp. 14-15, 1995.
Tanaka, N. et al., "Cellular Commitment to Oncogene-Induced Transformation or Apoptosis Is Dependent on the Transcription Factor IRF-1," Cell 77:829-839 (Jun. 1994).
Tanaka, N. et al., "Suppression of c-myc or fosB-induced cell transformation by the transcription factor IRF-1," Cancer Letts. 83:191-196 (1994).
Anderson, W.F. "Gene Therapy". Scientific Ambyion Sep. 1995, pp. 124-127.
Au et al., "Distinct activation of murine intergeron-.alpha. promotor region by IRF-1/SFG-2 and virus infection," Nucl. Acids Research 20(11):2877-2884 (1992).
Fujita et al., "Evidence for a nuclear factor(s), IRF-1, mediating induction and silencing properties to human IFN-.beta. gene regulatory elements," EBMO J. 7(11):3397-3405 (1988).
Fujita et al., "Induction of endogenous IFN-.alpha. and IFB-.beta. genes by a regulatory transcription factor, IRF-1," Nature 337:270-272 (1989).
Harada et al., "Absence of the type I IFN system in EC cells: activator (IRE-1) and repression (IRF-2) are developmentally transcriptional regulated," Cell 63:303-312 (1990).
Harada et al., "Anti-Oncogenic and Oncogenic Potentials of Interferon Regulatory Factors-1 and -2," Science 259:971-974 (1993).
Harada et al., "Structurally similar by functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN-inducible genes," Cell 58:729-739 (1989).
Itoh et al., "Assignment of the Human Interferon Regulatory Factor-1 (IRF1) Gene to Chromosome 5q23-q31," Genomics 10:1097-1099 (1991).
Le Beau et al., "Interleukin-4 and interleukin-5 map to human chromosome 5 in a region encoding growth factors and receptors and are deleted in myeloid leukemias with a del(5q)," Blood 73(3):647-650 (1989).
Maruyama et al., "Sequence of a cDNA coding for human IRF-1," Nucl. Acids Res. 17(8):3292 (1989).
Miyamoto et al., "Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-.beta. gene regulatory elements," Cell 54:903-913 (1988).
Naf et al., "Multimerization of AAGTGA and GAAAGT generates sequences that mediate virus inductibility by mimicking an interferon promoter element," PNAS USA 88:1369-1373 (1991).
Pederson, B. and Jensen, I.M., "Clinical and prognostic implications of chromosome 5q deletions: 96 high resolution studied patients," Leukemia 5(7):566-573 (1991).
Reis et al., "Critical role of a common transcription factor, IRF-1, in the regulation of IFN-.beta. and IFB-inducible genes," EMBO J. 11(1):185-193 (1992).
Stark, G.R. and Kerr, I.M., "Interferon-dependent signaling pathways: DNA elements, transcription factors, mutations, and effects of viral proteins", J. Interferon Research 12:147-151 (1992).
Watanabe et al., "Activation of IFN-.beta. element by IRF-1 requires a post-translational event in addition to IRF-1 synthesis," Nucl. Acid Res. 19(16):4421-4428 (1991).
Yamada et al., "Specific depletion of the B-cell population induced by aberrant expression of human interferon regulatory factor 1 gene in transgenic mice," PNAS USA 88:532-536 (1991).
Willman et al., "Deletion of IRF-1, Mapping to Chromosome 5q31.1, in Human Leukemia and Preleukemic Myelodysplasia," Science 259:968-971 (1993).
Supplementary Partial European Search Report for International Application No. EP 93922412.7 (Mar. 7, 1997).
Harada Hisashi
Pallavicini Maria G.
Tanaka Nobuyuki
Taniguchi Tadatsugu
Willman Cheryl L.
Low Christopher S. F.
Nguyen Dave Trong
Taniguchi Tadatsugu
The Regents of the University of California
The University of New Mexico
LandOfFree
Interferon regulatory factors 1 and 2 in the diagnosis of tumori does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interferon regulatory factors 1 and 2 in the diagnosis of tumori, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interferon regulatory factors 1 and 2 in the diagnosis of tumori will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-87166